Protection of the ischaemic heart: Investigations into the phenomenon of ischaemic preconditioning

Cardiovascular Journal of Africa

Volumn 20, Issue 1, 2009, Pages 43-51

  Lochner, A ^a   Marais, E ^a   Genade, S ^a   Huisamen, B ^a   Du Toit, E F ^a   Moolman, J A ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA ADRENERGIC RECEPTOR; CATECHOLAMINE; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC GMP; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN KINASE C;

CATECHOLAMINE RELEASE; ENZYME ACTIVATION; ENZYME INHIBITION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; ISCHEMIC PRECONDITIONING; NONHUMAN; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CYCLIC AMP; CYCLIC GMP; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RECEPTORS, ADRENERGIC; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 64649103651     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Murray CJ, Lopez AD. Alternate projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349: 1498-1504.
2. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
3. Kloner RA, Shook T, Entman EM, et al. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation 1998; 97: 1042-1045.
4. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 1113-1151.
5. Gross ER, Gross GJ. Ischemic preconditioning and myocardial infarction: an update and perspective. Drug Discov Today Dis Mech 2007; 43: 165-174.
6. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia/reperfusion injury. Physiol Rev 2008; 88: 581-609.
7. Moolman JA, Genade S, Winterbach R, et al. Preconditioning with a single episode of ischemia in the isolated working rat heart: effect on structure, mechanical function and energy metabolism for various durations of ischaemia. Cardiovasc Drugs Therap 1993; 9: 103-115.
8. Lochner A, Genade S, Moolman JA. Ischemic preconditioning: infarct size is a more reliable endpoint than functional recovery. Basic Res Cardiol 2003; 98: 337-346.
9. Downey JM, Davis AM, Cohen MV Signaling pathways in ischemic preconditioning. Heart Fail Rev 2007; 12: 181-188.
10. Downey JM, Davis AM, Cohen MV Unraveling the mysteries of classical preconditioning. J Mol Cell Cardiol 2005; 39: 845-848.
11. Schömig A, Dart AM, Dietz R, et al. Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A; Locally mediated release. Circ Res 1984; 55: 689-701.
12. Banerjee A, Locke-Winter C, Rogers K, Mitchell MD, et al. Preconditioning against myocardial dysfunction after ischaemia and reperfusion by an α-1 adrenergic mechanism. Circ Res 1993; 73: 656-670.
13. Moolman JA, Genade S, Tromp E, Lochner A. No evidence for mediation of ischaemic preconditioning by a,-adrenergic signal transduction pathway or protein kinase C in the isolated rat heart. Cardiovasc Drugs Therap 1996; 10: 125-136.
14. Lochner A, Marais E, Genade S, Moolman JA. Nitric oxide: a trigger for classic preconditioning? Am J Physiol 2000; 279: H2752-H2765.
15. Lochner A, Genade S, Tromp E, et al. Ischemic preconditioning and the beta-adrenergic signal transduction pathway. Circulation 1999; 100: 958-966.
16. Lochner A, Genade S, Tromp E, et al. Role of cyclic nucleotide phosphodiesterase in ischemic preconditioning. Mol Cell Biochem 1998; 186: 169-175.
17. Moolman JA, Hartley S, van Wyk J, Marais E, Lochner A. Inhibition of myocardial apoptosis by ischaemia and beta-adrenergic preconditioning is dependent on p38 MAPK. Cardiovasc Drugs Therap 2006; 20: 13-25.
18. Nasa Y, Yabe K, Takeo S. Beta-adrenoceptor stimulation-mediated preconditioning-like cardioprotection in perfused rat hearts. J Cardiovasc Pharmacol 1997; 29: 436-443.
19. Asimakis G, Inners-McBride K, Conti VR, Yang CJ. Transient beta adrenergic stimulation can precondition the rat heart against post-ischaemic contractile dysfunction. Cardiovasc Res 1994; 28: 1726-1734.
20. Robinet A, Hoizey G, Millart H. PI3-kinase, protein kinase C, and protein kinase A are involved in the trigger phase of beta 1-adrenergic preconditioning. Cardiovasc Res 2005; 66: 530-542.
21. Costa ADT, Garlid KD, West IC, et al. Protein kinase C transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 2005; 97: 329-336.
22. Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. JMol Cell Cardiol 1997; 29: 207-216.
23. Tritto I, D'Andrea D, Eramo N, et al. Oxygen radicals can induce preconditioning in rabbit hearts. Circ Res 1997; 80: 743-748.
24. Michel MC, Li Y, Heusch G. Mitogen-activated protein kinase in the heart. Naunyn-Schmiedeberg's Arch Pharmacol 2001; 363: 245-266.
25. Schultz R, Cohen MV, Behrends M, Downey JM, Heusch G. Signal transduction in preconditioning. Cardiovasc Res 2001; 52: 181-198.
26. Marais E, Genade S, Huisamen B, et al. Activation of p38 MAPK induced by a multi-cycle preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion. JMol Cell Cardiol 2001; 33: 769-778.
27. Schneider S, Chen W, Hon J, et al. Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning. Am J Physiol 2001; 280: H499-H508.
28. Lochner A, Genade S, Hattingh S, et al. Comparison between ischaemic and anisomycin-induced preconditioning: role of p38 MAPK. Cardiovasc Drugs Therap 2003; 17: 217-230.
29. Nagarkatti D, Sha'afi RI. Role of p38 MAP kinase in myocardial stress. JMol Cell Cardiol 1998; 30: 1651-1664.
30. Nakano A, Baines CP, Kim SO, et al. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart; evidence for involvement of p38 MAPK. Circ Res 2000; 86: 144-151.
31. Martin JL, Mestril R, Hilal-Dandau R, et al. Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 1997; 96: 4343-4348.
32. Marais E, Genade S, Salie R, et al. The temporal relationship between p38 MAPK and HSP27 activation in ischaemic and pharmacological preconditioning. Basic Res Cardiol 2005; 100: 35-47.
33. Marais E, Genade S, Lochner A. CREB activation and ischaemic preconditioning. Cardiovasc Drugs Therap 2008; 22: 3-17.
34. Nagy N, Shiroto K, Malik G, et al. Ischaemic preconditioning involves dual cardioprotective axes with p38 MAPK as upstream target. J Mol Cell Cardiol 2007; 42: 981-990.
35. Asimakis GK, Inners-McBride K, Medellin G, Conti V Ischemic preconditioning attenuates acidosis and postischemic dysfunction in isolated rat heart. Am J Physiol 1992; 163: H887-H894.
36. Volovsek A, Subramanian R, Rebousoin D. Effects of duration of ischaemia during preconditioning on mechanical function, enzyme release and energy production in the isolated working rat heart. J Mol Cell Cardiol 1992; 24: 1011-1019.
37. Moolman JA, Genade S, Tromp E, Lochner A. A comparison between ischemic preconditioning and anti-adrenergic interventions: cAMP, energy metabolism and functional recovery. Basic Res Cardiol 1996; 91: 219-233.
38. Sandhu R, Thomas U, Diaz RJ, Wilson GJ. Effect of ischemic preconditioning of the myocardium on cAMP. Circ Res 1996; 78: 137-147.
39. Sandhu R, Diaz RJ, Mao GD, Wilson GJ. Ischemic preconditioning: differences in protection and susceptibility to blockade with single-cycle vs multicycle transient ischemia. Circulation 1997; 96: 984-995.
40. Simonis G, Weinbrenner C, Strasser RH. Ischemic preconditioning promotes a transient, but not sustained translocation of protein kinase C and sensitization of adenylyl cyclase. Basic Res Cardiol 2003; 98: 104-113.
41. Opie LH. Heart Physiology. From Cell to Circulation. 4th edn. Philadelphia: Lippincott, Williams & Wilkens, 2004: 188.
42. Maulik N, Yoshida T, Zu X-L, et al. Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. Am J Physiol 1998; 275: H 1857-H1864.
43. Vahlhaus C, Schulz R, Post H, et al. No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Circ Res 1996; 79: 407-414.
44. Sanada S, Kitakaze M, Papst PJ, et al. Role of phasic dynamism of p38 mitogen-activated protein kinase activation or ischemic preconditioning of the canine heart. Circ Res 2001; 88: 175-184.
45. Weinbrenner C, Liu GS, Cohen MV, Downey JM. Phosphorylation of tyrosine 182 of p38 mitogen activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J Mol Cell Cardiol 1997; 29: 2383-2391.
46. Kim SO, Baines CP, Critz SD, et al. Ischemia-induced activation of heat shock protein 27 and casein kinase 2 in the preconditioned rabbit heart. Biochem Cell Biol 1999; 77: 559-567.
47. Marais E. Role of cAMP, cGMP and p38 MAPK in preconditioning of the ischaemic myocardium. PhD thesis, University of Stellenbosch, 2002.
48. Sato M, Cordis GA, Maulik N, Das DK. SAPKs regulation of ischemic preconditioning. Am J Physiol 2000; 279: H901-H907.
49. MacKay K, Mochley-Rosen D. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. J Biol Chem 1999; 274: 6272-6279.
50. Schneider S, Chen W, Hou J, Steenbergen C, Murphy E. Inhibition of p38MAPKα/β reduces ischemic injury and does not block protective effects of preconditioning. Am J Physiol 2001; 280: H499-H505.
51. Saurin AT, Martin JC, Heads RJ, et al. The role of differential activation of p38 mitogen activated protein kinase in preconditioned ventricular myocytes. Faseb J 2000; 14: 2237-2246.
52. Mocanu MM, Baxter GF, Yue Y, Critz SD, Yellon DM. The p38 MAPK inhibitor, SB203580, abrogates preconditioning, but timing of administration is critical. Basic Res Cardiol 2000; 95: 472-478.
53. Kaiser RA, Bueno OF, Lips DJ, et al. Targeted inhibition of p38 mitogen activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 2004; 279: 15524-15530.
54. Bassi R, Heads R, Marber MS, Clark JE. Targeting p38 MAPK in the ischaemic heart: kill or cure? Curr Opin Pharmacol 2008; 8: 141-146.
55. Nakamura M, Wang NP, Zhao ZQ, et al. Preconditioning decreases Bax expression, PMN accumulation and apoptosis in reperfused rat hearts. Cardiovasc Res 2000; 45: 661-670.
56. Piot CA, Padmanabam D, Ursell PC, et al. Ischemic preconditioning decreases apoptosis in rat hearts in vivo. Circulation 1997; 96: 1598-1604.
57. Freude B, Masters TN, Robicsek F, et al. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J. Mol Cell Cardiol 2000; 32: 197-208.
58. Krijnen PAJ, Nijmeijer R, Meijer CJLM, et al. Apoptosis in myocardial ischaemia and infarction. J Clin Path 2002; 55: 801-811.
59. Yin T, Sandhu G, Wolfgang CD, et al. Tissue specific patterns of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem 1997; 272: 19943-19950.
60. Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999; 99: 1585-1691.
61. Chi NC, Karliner JS. Molecular determinants of responses to myocardial ischaemia/reperfusion injury: Focus on hypoxia-inducible and heat shock factors. Cardiovasc Res 2004; 61: 437-447.
62. Heads RJ, Yellon DM, Latchman DS. Differential cytoprotection against heat stress or hypoxia following expression of specific stress protein genes in myogenic cells. J Mol Cell Cardiol 1995; 27: 1669-1678.
63. Brar BS, Stephanou AS, Wagstaff MJD, Coffin RS, Marber MS, Engelman G, et al. Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as thermal or ischaemic stress. J Mol Cell Cardiol 1999; 31: 135-146.
64. Efthmiou CA, Mocanu MM, de Belleroche J, Wells DS, Latchman DS, Yellon DM. Heat shock protein 27 protects the heart against myocardial infarction. Basic Res Cardiol 2004 ; 99: 392-394.
65. Georgopoulos C, Welch WJ. Roles of major heat shock proteins as molecular chaperones. Ann Rev Cell Biol 1993; 9: 601-635.
66. Larsen JK, Yamboliev IA, Weber LA, Gerthoffer WT. Phosphorylation of the 27kDA heat shock protein via p38 MAPK kinase and MAPKAP kinase in smooth muscle. Am J Physiol 1997; 273: 2930-2940.
67. Huot J, Houle F, Spitz DR, Landry J. HSP27 phosphorylation-mediated resistance against actin fragmentation and cell death induced by oxidative stress. Cancer Res 1996; 56: 273-279.
68. Schneider GB, Hamano H, Cooper LF. In vivo evaluation of HSP27 as an inhibitor of actin polymerization: HSP27 limits actin stress fiber and focal adhesion formation after heart shock. J Cell Physiol 1998; 177: 575-584.
69. Lu YY, Chen L, Cai XL, Yang HT. Overexpression of heart shock protein 27 protects ischaemia/reperfusion-induced cardiac dysfunction via stabilization of troponin I and T. Cardiovasc Res 2008; 79: 500-508.